| scholarly article | Q13442814 |
| P50 | author | Felicity T. Enders | Q37368360 |
| Kris V. Kowdley | Q110296712 | ||
| Tanya L. Hoskin | Q112864195 | ||
| P2093 | author name string | Keith D Lindor | |
| Jan Petz | |||
| Jill Keach | |||
| Prabin Thapa | |||
| M Edwyn Harrison | |||
| Alex S Befeler | |||
| Debra King | |||
| Roberta Jorgensen | |||
| Timothy McCashland | |||
| Denise Harnois | |||
| Carol Sargeant | |||
| Velimir A C Luketic | |||
| Jody Mooney | |||
| Ellen Miceli | |||
| Jeff Schmoll | |||
| Julie Braaten | |||
| Tamara Bernard | |||
| P2860 | cites work | Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin | Q34375582 |
| Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial | Q34498312 | ||
| A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation | Q37383640 | ||
| High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis | Q43618408 | ||
| A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 | ||
| Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles | Q44165186 | ||
| Colchicine treatment of primary sclerosing cholangitis | Q44184207 | ||
| High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective | Q46722756 | ||
| High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study | Q46802343 | ||
| Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community | Q47404936 | ||
| A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis | Q72754055 | ||
| Oral budesonide in the treatment of primary sclerosing cholangitis | Q73009511 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver | Q73491970 | ||
| A revised natural history model for primary sclerosing cholangitis | Q74042025 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Tacrolimus for the treatment of primary sclerosing cholangitis | Q80085794 | ||
| Primary sclerosing cholangitis | Q81781641 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ascending cholangitis | Q603644 |
| primary sclerosing cholangitis | Q1058608 | ||
| sclerosing cholangitis | Q18554727 | ||
| P304 | page(s) | 808-814 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | |
| P478 | volume | 50 |
| Q91789058 | A Cholangioscopy-Based Novel Classification System for the Phenotypic Stratification of Dominant Bile Duct Strictures in Primary Sclerosing Cholangitis-the Edmonton Classification |
| Q91178791 | A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis |
| Q64052770 | A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease |
| Q38584285 | A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis |
| Q41608266 | A gentleman with anemia and cholestasis |
| Q38393029 | A morphological and immunohistochemical study of the effects of prednisolone or ursodeoxycholic acid on liver histology in feline lymphocytic cholangitis |
| Q35778052 | A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. |
| Q26771816 | A review of the medical treatment of primary sclerosing cholangitis in the 21st century |
| Q37613973 | ABCB4 Disease Presenting with Cirrhosis and Copper Overload-Potential Confusion with Wilson Disease |
| Q55059041 | ACG Clinical Guideline: Primary Sclerosing Cholangitis. |
| Q30454106 | ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study |
| Q35162765 | Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis |
| Q39238694 | Advances in primary sclerosing cholangitis |
| Q34672135 | Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis |
| Q92064845 | An update on treatment options for primary sclerosing cholangitis |
| Q98465718 | Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases |
| Q38103631 | Autoimmune hepatitis in diverse ethnic populations and geographical regions |
| Q89737518 | Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases |
| Q34083354 | Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression |
| Q24186230 | Bile acid derivatives for people with primary sclerosing cholangitis |
| Q35181443 | Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis |
| Q24234678 | Bile acids for primary sclerosing cholangitis |
| Q100416036 | Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis |
| Q34108895 | Biliary physiology and disease: reflections of a physician-scientist |
| Q26766699 | Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver |
| Q92465727 | British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis |
| Q61796242 | Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies |
| Q35490961 | Cancer surveillance in patients with primary sclerosing cholangitis |
| Q38383394 | Characteristics and outcome of autoimmune liver disease in Asian children. |
| Q44247201 | Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons |
| Q38757248 | Child with Jaundice and Pruritus: How to Evaluate? |
| Q92326834 | Cholestatic liver diseases: An era of emerging therapies |
| Q57111104 | Cholestatic liver diseases: new targets, new therapies |
| Q59528257 | Chronische cholestatische Leberkrankheiten |
| Q28660820 | Cirrhosis and other liver disease in cystic fibrosis |
| Q33709930 | Clinical application of transcriptional activators of bile salt transporters |
| Q42383585 | Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis |
| Q64044703 | Clinical guidelines for primary sclerosing cholangitis 2017 |
| Q51643325 | Clinical trials and their translation in hepatology: past, present, and future. |
| Q26772310 | Combination antiretroviral studies for patients with primary biliary cirrhosis |
| Q34752957 | Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells |
| Q33916319 | Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis |
| Q34428848 | Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference |
| Q26765804 | Controversies in the management of primary sclerosing cholangitis |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q37847138 | Current management of primary sclerosing cholangitis in pediatric patients |
| Q38055205 | Current pharmacotherapy for cholestatic liver disease |
| Q35066561 | Current research on the treatment of primary sclerosing cholangitis |
| Q60920560 | Current therapies and novel approaches for biliary diseases |
| Q90603976 | Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients |
| Q38704228 | Cystic fibrosis from the gastroenterologist's perspective |
| Q28655881 | Cystic fibrosis related liver disease--another black box in hepatology |
| Q44511582 | Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies |
| Q52343068 | Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. |
| Q22241416 | Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease |
| Q51726466 | Diagnosis and management of primary sclerosing cholangitis. |
| Q27003179 | Diagnosis and management of the overlap syndromes of autoimmune hepatitis |
| Q37964636 | Diagnostic and therapeutic challenges in pediatric primary sclerosing cholangitis |
| Q64250068 | Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe? |
| Q64039289 | Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases |
| Q38751076 | Emerging pharmacologic therapies for primary sclerosing cholangitis |
| Q92864604 | Emerging therapies for PBC |
| Q90722936 | Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities |
| Q38748384 | Emerging treatments for primary sclerosing cholangitis |
| Q37337378 | Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice |
| Q22241217 | Epidemiology and clinical course of Crohn's disease: results from observational studies |
| Q39746487 | Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. |
| Q38849427 | Evidence-based clinical practice guidelines for liver cirrhosis 2015. |
| Q37957967 | Evolving concepts in primary sclerosing cholangitis |
| Q36572561 | FXR and PXR: potential therapeutic targets in cholestasis. |
| Q33431380 | Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis |
| Q92003565 | From pruritus to CREST syndrome in a middle aged woman |
| Q35933236 | Functional and structural features of cholangiocytes in health and disease |
| Q58551479 | Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis |
| Q53627194 | Gastrointestinal Manifestations of Cystic Fibrosis. |
| Q38814158 | Hepatic manifestations of inflammatory bowel diseases |
| Q37812845 | Hepatobiliary Manifestations of Gastrointestinal and Nutritional Disorders |
| Q33966083 | Hepatobiliary complications of inflammatory bowel disease |
| Q37905969 | Hepatobiliary disorders and complications of inflammatory bowel disease |
| Q37317444 | Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. |
| Q26829300 | Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk |
| Q34147508 | Hepatocyte Death: A Clear and Present Danger |
| Q37701805 | Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease |
| Q85610815 | Hepatopancreatobiliary manifestations of inflammatory bowel disease |
| Q43284332 | High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? |
| Q37117971 | High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis |
| Q28237152 | High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis |
| Q47823578 | Hydrodynamics of bile flow Lessons from computational modelling. |
| Q57108417 | IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis |
| Q38957567 | Imaging of autoimmune biliary disease |
| Q37559266 | Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient |
| Q51165355 | In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. |
| Q59813006 | Inhibitory Effect of Ursodeoxycholic Acid on Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans |
| Q36204422 | Interaction of gut microbiota with bile acid metabolism and its influence on disease states |
| Q52601885 | Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting. |
| Q33754301 | Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice |
| Q26782863 | Liver Transplantation for Patients with Cholestatic Liver Diseases |
| Q35028987 | Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity |
| Q38774857 | Management of cholestatic disease in 2017. |
| Q84808600 | Management of primary sclerosing cholangitis |
| Q35962107 | Management of primary sclerosing cholangitis: conventions and controversies |
| Q93140815 | Medical management of primary sclerosing cholangitis |
| Q45151761 | Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis |
| Q36349449 | Method for microRNA isolation from clinical serum samples |
| Q36197335 | Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. |
| Q42315968 | Neonatal cholestasis due to primary sclerosing cholangitis |
| Q92565000 | Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics |
| Q47223909 | New therapies target the toxic consequences of cholestatic liver disease |
| Q37892297 | New treatment strategies for primary sclerosing cholangitis |
| Q27006992 | Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? |
| Q42406740 | Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic |
| Q84273556 | Novel developments in IBD-related sclerosing cholangitis |
| Q64970819 | Novel treatments in primary sclerosing cholangitis. |
| Q39216355 | Old and new treatments for primary biliary cholangitis |
| Q37334783 | Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis |
| Q59384428 | Overlap syndrome: A real syndrome? |
| Q26830851 | Overlap syndromes: an emerging diagnostic and therapeutic challenge |
| Q34623557 | Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches |
| Q27015831 | Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management |
| Q38919832 | Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis |
| Q89690610 | Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study |
| Q38833243 | Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. |
| Q37681567 | Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid |
| Q24193305 | Pharmacological treatments for primary sclerosing cholangitis: a network meta-analysis |
| Q34351552 | Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis |
| Q89639221 | Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist |
| Q42765644 | Prevention and treatment of intestinal failure-associated liver disease in children |
| Q26781780 | Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective |
| Q56442935 | Primary Sclerosing Cholangitis |
| Q88616701 | Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning |
| Q55497458 | Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. |
| Q38107484 | Primary Sclerosing Cholangitis: Current and Future Management Strategies |
| Q91642487 | Primary Sclerosing Cholangitis: Epidemiology, Genetics, Diagnosis, and Current Management |
| Q26744040 | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| Q56442936 | Primary sclerosing cholangitis |
| Q57116825 | Primary sclerosing cholangitis |
| Q38417642 | Primary sclerosing cholangitis - the Norwegian experience |
| Q85407194 | Primary sclerosing cholangitis and bile acids |
| Q37694337 | Primary sclerosing cholangitis and pregnancy |
| Q93140726 | Primary sclerosing cholangitis during childhood and adolescence |
| Q41881798 | Primary sclerosing cholangitis in patient with celiac disease complicated by cholecystic empyema and acute pancreatitis |
| Q38485235 | Primary sclerosing cholangitis: a clinical update |
| Q26829216 | Primary sclerosing cholangitis: diagnosis and treatment |
| Q36955053 | Primary sclerosing cholangitis: diagnosis, prognosis, and management |
| Q37962395 | Primary sclerosing cholangitis: is any treatment worthwhile? |
| Q37799533 | Primary sclerosing cholangitis: overview and update |
| Q43172275 | Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC? |
| Q46933007 | Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis |
| Q40738996 | Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis |
| Q47121237 | Protective effect of dehydroandrographolide on obstructive cholestasis in bile duct-ligated mice |
| Q34464043 | Recent advances in the development of farnesoid X receptor agonists |
| Q42406650 | Recent developments in the management of idiopathic cholestatic liver disease |
| Q38019989 | Recent insights in primary sclerosing cholangitis |
| Q43046283 | Recurrence and rejection in liver transplantation for primary sclerosing cholangitis |
| Q37892612 | Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34403316 | Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis |
| Q26796355 | Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists |
| Q38129543 | Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis |
| Q43585465 | Sclerosing cholangitis in critically ill patients: an important and easily ignored problem based on a German experience |
| Q43082859 | Sclerosing cholangitis: pediatric perspective |
| Q54982596 | Searching for Bacterial Biofilm in Recurrent Cholangitis in Primary Sclerosing Cholangitis: A Case Presentation and Introduction of an Unexplored Disease Mechanism. |
| Q38049779 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations |
| Q48253693 | Short-term prognostic factors for primary sclerosing cholangitis |
| Q56333933 | Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease |
| Q63247975 | Strategies for management of pediatric cystic fibrosis liver disease |
| Q38595151 | Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q37866339 | Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis |
| Q39037242 | Systematic review: recurrent autoimmune liver diseases after liver transplantation. |
| Q45895068 | Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model |
| Q35942610 | The Cholangiopathies |
| Q88210045 | The IBD and PSC Phenotypes of PSC-IBD |
| Q91126971 | The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis |
| Q28068996 | The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood |
| Q39040911 | The ascending pathophysiology of cholestatic liver disease. |
| Q34993108 | The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study |
| Q38789869 | The intestinal microbiome and paediatric liver disease |
| Q38622370 | The management of autoimmunity in patients with cholestatic liver diseases |
| Q38037392 | The overlap syndromes of autoimmune hepatitis |
| Q33966445 | The predictors of the presence of varices in patients with primary sclerosing cholangitis |
| Q37024748 | The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study |
| Q35958534 | Therapeutic targeting of bile acids |
| Q38058982 | Treatment of NASH with ursodeoxycholic acid: pro. |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
| Q61443475 | Treatment of primary sclerosing cholangitis in children |
| Q37777156 | Treatment options for primary sclerosing cholangitis |
| Q89052836 | Update in the Care and Management of Patients with Primary Sclerosing Cholangitis |
| Q46719222 | Update in the management of extraintestinal manifestations of inflammatory bowel disease |
| Q55333522 | Update on pharmacotherapies for cholestatic liver disease. |
| Q38058981 | Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action |
| Q90221990 | Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model |
| Q37919924 | Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. |
| Q55058073 | Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). |
| Q39170726 | Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. |
| Q52691507 | Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms. |
| Q89677698 | Ursodeoxycholic acid use is associated with significant risk of morbidity and mortality in infants with cholestasis: A strobe compliant study |
| Q38125078 | Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis |
| Q48151874 | Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease |
| Q39216625 | Vitamin A deficiency in chronic cholestatic liver disease -is vitamin A therapy beneficial ? |
Search more.